CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF

The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia. 2. The crystalline form of AMG 900 according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of a mesylate salt claim 1 , a bismesylate salt claim 1 , a hydrochloride salt claim 1 , a besylate salt claim 1 , a tosylate salt claim 1 , an acetate salt claim 1 , a sulfate salt and a fumarate salt.3. The crystalline form of AMG 900 according to claim 2 , wherein the pharmaceutically acceptable salt selected from a mesylate salt claim 2 , a bismesylate salt claim 2 , a besylate salt and a tosylate salt.4. The crystalline form of AMG 900 according to claim 3 , wherein the pharmaceutically acceptable salt selected from a mesylate salt or a bismesylate salt.5. A crystalline form A of a mesylate salt of AMG 900 according to characterized by an X-ray powder diffraction (XRPD) diagram comprising peaks at the following angles of refraction 2 theta: 9.89+/−0.16° claim 4 , 12.96+/−0.10° claim 4 , 16.52+/−0.10° claim 4 , 17.84+/−0.16° claim 4 , 20.05+/−0.10° and 21.55+/−0.19°.6. A crystalline form A of a mesylate salt of the AMG 900 according to claim 5 , characterized as providing an X-ray powder diffraction pattern substantially as shown in .7. A crystalline form of a bismesylate salt of AMG 900 according to characterized by an X-ray powder diffraction (XRPD) diagram comprising peaks at the following angles of refraction 2 theta: 10.7+/−0.2° claim 4 , 12.7+/−0.2° claim 4 , 15.17+/−0.20° claim 4 , 20.7+/−0.2° and 24.8+/−0.2°.8. ...

SOLID STATE FORMS

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

SOLID STATE FORMS

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

SOLID STATE FORMS

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition. 1. A compound , wherein the compound is a crystalline form of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2 ,3-d]pyrimidin-2(1H)-one (Compound 1) or an atropisomer thereof.2. The compound of claim 1 , wherein the compound is the M atropisomer of Compound 1.3. The compound of or claim 1 , wherein the compound is a crystalline anhydrous form of Compound 1.4. The compound of any one of - claim 1 , wherein the compound is characterized by a powder X-ray diffraction pattern comprising peaks at 9.0 claim 1 , 12.0 claim 1 , 12.6 claim 1 , and 19.0±0.2 degrees 2 theta as measured by x-ray powder diffraction using an x-ray wavelength of 1.54 Å.5. The compound of any one of - claim 1 , wherein the compound is characterized by a powder X-ray diffraction pattern comprising at least three peaks selected from 8.8 claim 1 , 9.0 claim 1 , 10.8 claim 1 , 12.0 claim 1 , 12.6 claim 1 , 12.8 claim 1 , 13.6 claim 1 , 14.2 claim 1 , 15.0 claim 1 , 15.4 claim 1 , 18.0 claim 1 , 18.6 claim 1 , 18.7 claim 1 , 19.0 claim 1 , 19.9 claim 1 , 20.0 claim 1 , 22.9 claim 1 , and 25.0±0.2 degrees 2 theta as measured by x-ray powder diffraction using an x-ray wavelength of 1.54 Å.6. The compound of any one of - claim 1 , wherein the compound is characterized by a powder X-ray diffraction pattern comprising at least five peaks selected from 8.8 claim 1 , 9.0 claim 1 , 10.8 claim 1 , 12.0 claim 1 , 12.6 claim 1 , 12.8 claim 1 , 13.6 claim 1 , 14.2 claim 1 , 15.0 claim 1 , 15.4 claim 1 , 18.0 claim 1 , 18.6 claim ...

POLYMORPHS OF A CARDIAC TROPONIN ACTIVATOR

Provided herein are free base crystalline forms, crystalline salts, and solvates of Compound B.

SOLID STATE FORMS

The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

POLYMORPHS AND COCRYSTALS OF A CARDIAC TROPONIN ACTIVATOR

Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Solid state forms

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof

The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline foms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.

solid state forms

La presente divulgación proporciona formas cristalinas y amorfas de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2- propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona, incluyendo varias formas anhidras, de hidrato y de solvato, y formas en estado sólido de las mismas, composiciones farmacéuticas y métodos de tratamiento de una enfermedad mediada por la inhibición de KRAS G12C. The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S )-2-methyl-4-(2-propenyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including various anhydrous, hydrate and solvate forms, and solid forms solid thereof, pharmaceutical compositions and methods of treating a disease mediated by KRAS G12C inhibition.

Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof.

La presente invención se relaciona con formas cristalinas y formas co-cristalinas de sales farmacéuticamente aceptables del compuesto, N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil) -4-(4-metil-2-tienil)-1-ftalazinamina (AMG 900), y las composiciones farmacéuticas que comprenden las formas cristalinas y co-cristalinas del mismo. La invención proporciona además los usos de las formas cristalinas y composiciones, para tratar cáncer, incluyendo diversos tipos de tumores sólidos y cáncer hematológico incluyendo mieloma y leucemia.

Crystalline forms of pharmaceutically acceptable salts of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine and uses thereof

【課題】黒色腫及び白血病を含む様々な種類の固形腫瘍及び血液癌が含まれる癌を治療するための、結晶形態及び組成物の使用を提供する。【解決手段】下記式を有する化合物Ｎ－（４－（（３－（２－アミノ－４－ピリミジニル）－２－ピリジニル）オキシ）フェニル）－４－（４－メチル－２－チエニル）－１－フタラジンアミン（ＡＭＧ９００）の薬学的に許容される塩の結晶形態及び共結晶形態、並びに前記結晶形態及び共結晶形態を含むその薬学的組成物を提供する。TIFF2022068350000060.tif56165【選択図】図４

solid state shapes

formas em estado sólido. a presente divulgação proporciona formas cristalinas e amorfas de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2s)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1h)-ona, incluindo várias formas anidras, de hidrato e de solvato, e suas formas em estado sólido, composições farmacêuticas e métodos de tratamento de uma doença mediada por inibição de kras g12c. solid state forms. the present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2s )-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1h)-one, including various anhydrous, hydrate and solvate forms, and forms thereof solid state, pharmaceutical compositions and methods of treating a disease mediated by inhibition of kras g12c.

Polymorphs of a cardiac troponin activator

Provided herein are free base crystalline forms, crystalline salts, and solvates of Compound B.

Solid state forms

The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Solid state forms

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

[UNK]

Polymorphs and cocrystals of a cardiac troponin activator

Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Solid state forms

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Amorphous and crystalline forms of mci-1 antagonists

Disclosed herein are crystalline and amorphous forms of (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (AMG 176), and salts and hydrates thereof. Also disclosed are methods of making the crystalline and amorphous forms, and methods of treating diseases and disorders with the crystalline and amorphous forms.

Formas en estado sólido

Reivindicación 1: Una forma I de sal clorhidrato cristalina de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona (Compuesto 1). Reivindicación 4: La forma I de sal clorhidrato cristalina de Compuesto 1 de la reivindicación 1, en la que dicha forma se caracteriza por al menos tres picos, al menos cinco picos o al menos siete picos seleccionados entre un patrón de difracción de rayos X de polvo que comprende picos en grados 2 theta de ángulo de difracción a aproximadamente 6.6, 8.9, 10.9, 13.7, 14.2, 15.1, 18.0, 19.0 y 21.1. Reivindicación 20: Una forma II de sal clorhidrato cristalina de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona (Compuesto 1). Reivindicación 23: La forma II de sal clorhidrato cristalina de Compuesto 1 de la reivindicación 20, en la que dicha forma II se caracteriza por al menos tres picos, al menos cinco picos o al menos siete picos seleccionados entre un patrón de difracción de rayos X de polvo que comprende picos en grados 2 theta de ángulo de difracción a aproximadamente 6.0, 6.3, 8.2, 10.6, 11.2, 12.7, 13.6, 14.3, 16.1, 16.5, 17.2, 21.6 y 21.4. Reivindicación 40: Una forma III de sal clorhidrato cristalina de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona (Compuesto 1). Reivindicación 43: La forma III de sal clorhidrato cristalina de Compuesto 1 de la reivindicación 40, en la que dicha forma III se caracteriza por al menos tres picos, al menos cinco picos o al menos siete picos seleccionados entre un patrón de difracción de rayos X de polvo que comprende picos en grados 2 theta de ángulo de difracción a aproximadamente 6.4, 8.4, 11.0, 11.2, 12.7, 13.6, 13.9, 15.0, 15.6, 16.6, 16.7, 16.8 y 21.2. Reivindicación 64: Una forma IV ...

Formas en estado sólido.

La presente invención proporciona una forma cristalina y sales estables de 6-fluoro-7- (2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2- propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1- piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona, incluyendo varias formas de sal de clorhidrato, una forma de sal de fosfato, una forma de sal de mesilato, y formas en estado sólido de las mismas, composiciones farmacéuticas y métodos de tratamiento de una enfermedad mediada por la inhibición de KRAS G12C.

Sicherungsvorrichtung für Geschoßzünder, insbesondere von Gewehrgranaten

Sicherungsvorrichtung für Geschoßzünder

Zuendvorrichtung fuer gewehrgranaten

Polymorphs and cocrystals of a cardiac troponin activator

Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Polimorfos y cocristales de un activador de troponina cardíaca

En el presente documento se proporcionan formas cristalinas de base libre, sales cristalinas, solvatos, base libre amorfa y cocristales del Compuesto A.

Polimorfos y cocristales de un activador de la troponina cardiaca.

Se proporcionan aquí formas cristalinas de base libre, sales cristalinas, solvatos, base libre amorfa y cocristales del compuesto A.

Polymorphs and cocrystals of a cardiac troponin activator

Polimorfos y cocristales de un activador de la troponina cardíaca.

En el presente documento se proporcionan formas cristalinas de base libre, sales cristalinas, solvatos, base libre amorfa y cocristales del Compuesto A.

Forma cristalina anidra de base livre do composto a, forma cristalina mono-hidratada de base livre do composto a, forma cristalina do composto a e diclorometano, forma cristalina do composto a e nitrometano, forma cristalina do composto a e hexafluoro-2-propanol, cocristal, composição farmacêutica, e, método para tratar insuficiência cardíaca

forma cristalina anidra de base livre do composto a, forma cristalina mono-hidratada de base livre do composto a, forma cristalina do composto a e diclorometano, forma cristalina do composto a e nitrometano, forma cristalina do composto a e hexafluoro-2-propanol, cocristal, composição farmacêutica, e, método para tratar insuficiência cardíaca. neste documento, são fornecidas formas cristalinas de base livre, sais cristalinos, solvatos, base livre amorfa e cocristais do composto a.

Amorphous and crystalline forms of mcl-1 antagonists

Disclosed herein are crystalline and amorphous forms of (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2H, 15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0 3,6 ,0 19,24 ]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (AMG 176): and salts and hydrates thereof. Also disclosed are methods of making the crystalline and amorphous forms, and methods of treating diseases and disorders with the crystalline and amorphous forms.

Solid state forms

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxypheny1)-1-(4-methy1-2-(2-propany1)-3-pyridiny1)-4-((2S)-2-methyl-4-(2-propenoy1)-1-piperazinyl)pyrido[2,3-dlpyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Predicting shelf life stability of lyophilized drug products

A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment. The method also includes computing, by implementing a computational model and at each of a plurality of virtual time steps, a change in water amount or concentration in the virtual cake, virtual air within the virtual vial, and the virtual stopper, in part by applying the model parameters to the computational model. The method also includes generating information for display to a user via a user interface.

Predicting shelf life stability of lyophilized drug products

A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment. The method also includes computing, by implementing a computational model and at each of a plurality of virtual time steps, a change in water amount or concentration in the virtual cake, virtual air within the virtual vial, and the virtual stopper, in part by applying the model parameters to the computational model. The method also includes generating information for display to a user via a user interface.

Predicting shelf life stability of lyophilized drug products

A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment. The method also includes computing, by implementing a computational model and at each of a plurality of virtual time steps, a change in water amount or concentration in the virtual cake, virtual air within the virtual vial, and the virtual stopper, in part by applying the model parameters to the computational model. The method also includes generating information for display to a user via a user interface.

Predicting Shelf Life Stability of Lyophilized Drug Products

A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment. The method also includes computing, by implementing a computational model and at each of a plurality of virtual time steps, a change in water amount or concentration in the virtual cake, virtual air within the virtual vial, and the virtual stopper, in part by applying the model parameters to the computational model. The method also includes generating information for display to a user via a user interface.

Predicting shelf life stability of lyophilized drug products

A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment. The method also includes computing, by implementing a computational model and at each of a plurality of virtual time steps, a change in water amount or concentration in the virtual cake, virtual air within the virtual vial, and the virtual stopper, in part by applying the model parameters to the computational model. The method also includes generating information for display to a user via a user interface.

Crystalline forms of an mcl-1 inhibitor

Disclosed herein are crystalline forms of (4S,7aR,9aR, 10R, 11E, 14S, 15R)-6'-chloro-10-methoxy-14, 15- dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10, 13, 14, 15-decahydro- 2'H, 3H, 5H-spiro[1,19-etheno-1616-cyclobuta[i] [1,4] oxazepino[3, 4-f] [1,2,7]thiadiazacyclohexadecine-4,1'- naphthalene]-16, 16, 18(7H, 17H)-trione (AMG 397): (AMG 397), hydrates, and solvates thereof. Also disclosed are methods of making the crystalline forms, and methods of treating diseases and disorders with the crystalline forms.

Rostfreier,austenitischer und nicht-magnetischer Stahl.

Sicherungsvorrichtung fuer geschosszuender, insbesondere von gewehrgranaten

Crystalline salt and solvate forms of murizatoclax (amg 397)

Disclosed herein are salt and solvate forms of (4S,7aR,9aR, 10R, 11 E,14S, 15R)-6'-chloro-10-methoxy- 14, 15-dimethyI- 10-{[(9aR)-octahydro-2H-pyrido[1, 2-a] py razi n-2-yI] methyl}-3', 4', 7 a, 8, 9, 9 a, 10, 13, 14, 15-decahydro- 2'H, 3H, 5H-spiro[1, 19-etheno-1616-cyclobuta[i] [1, 4] oxazepino[3, 4-f] [1, 2, 7]thiadIazacyclohexadecine-4, 1 naphthalene]-16, 16, 18(7H, 17H)-trione (AMG 397): (AMG 397), such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.

Formas amorfas en estado sólido útiles como inhibidores de kras g12c

La invención actual se refiere a formas amorfas de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido(2,3-d)pirimidin-2(1H)-ona (Compuesto 1) o un atropisómero de la misma, composiciones que comprenden las formas amorfas y un excipientes farmacéuticamente aceptable.

Capa para auto

Compostos de formas amorfas, composição farmacêutica comprendendo os mesmos e uso destes para tratamento de câncer com uma mutação kras g12c

A presente divulgação proporciona formas cristalinas e amorfas de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4- ((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona, incluindo várias formas anidras, de hidrato e de solvato, e suas formas em estado sólido, composições farmacêuticas e métodos de tratamento de uma doença mediada por inibição de KRAS G12C.